S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:GRVI

Grove Stock Competitors

$4.24
-0.06 (-1.40%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.14
$4.37
50-Day Range
$3.90
$5.12
52-Week Range
$3.84
$9.37
Volume
56,038 shs
Average Volume
74,460 shs
Market Capitalization
$60.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Grove (NASDAQ:GRVI) Vs. CGC, TLRY, USNA, CRON, ACB, SNDL, CDXC, HEXO, IMCC, and NAII

Should you be buying Grove stock or one of its competitors? The main competitors of Grove include Canopy Growth (CGC), Tilray (TLRY), USANA Health Sciences (USNA), Cronos Group (CRON), Aurora Cannabis (ACB), Sundial Growers (SNDL), ChromaDex (CDXC), HEXO (HEXO), IM Cannabis (IMCC), and Natural Alternatives International (NAII). These companies are all part of the "medicinals & botanicals" industry.These companies are all part of the "medicinals & botanicals" industry.

Grove vs.

Grove (NASDAQ:GRVI) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability.

Grove has higher earnings, but lower revenue than Tilray.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grove$24.09 million2.50$2.98 millionN/AN/A
Tilray$513.09 million5.26-$367.42 million-$1.91-3.03

Tilray has a consensus target price of $12.54, suggesting a potential upside of 116.58%. Given Tilray's higher possible upside, analysts plainly believe Tilray is more favorable than Grove.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grove
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Tilray
1 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.15

Grove has a net margin of 0.00% compared to Tilray's net margin of -66.64%. Grove's return on equity of 0.00% beat Tilray's return on equity.

Company Net Margins Return on Equity Return on Assets
Grove N/A N/A N/A
Tilray -66.64% -2.57% -1.88%

Tilray received 442 more outperform votes than Grove when rated by MarketBeat users.

CompanyUnderperformOutperform
GroveN/AN/A
TilrayOutperform Votes
442
61.47%
Underperform Votes
277
38.53%

0.6% of Grove shares are owned by institutional investors. Comparatively, 12.1% of Tilray shares are owned by institutional investors. 3.0% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Tilray had 6 more articles in the media than Grove. MarketBeat recorded 6 mentions for Tilray and 0 mentions for Grove. Grove's average media sentiment score of 1.11 beat Tilray's score of 0.17 indicating that Grove is being referred to more favorably in the media.

Company Overall Sentiment
Grove Positive
Tilray Neutral

Summary

Tilray beats Grove on 8 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Grove (NASDAQ:GRVI) vs. Its Competitors

TypeGroveMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$60.24M$708.30M$4.67B$6.90B
Dividend YieldN/A2.03%2.04%2.91%
P/E RatioN/A4.8916.9018.31
Price / Sales2.5036.065,779.21225.01
Price / Cash14.2310.8162.3168.48
Price / Book2.853.847.578.87
Net Income$2.98M-$80.34M$98.79M$156.27M
7 Day Performance-9.79%-8.82%-7.56%-6.58%
1 Month Performance0.24%-11.59%-14.95%-11.29%
1 Year PerformanceN/A-37.67%-24.78%-12.14%

Grove Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGC
Canopy Growth
1.1749 of 5 stars
$7.29
-3.7%
$20.36
-179.3%
-78.4%$2.87B$414.03M-2.743,259
TLRY
Tilray
1.6918 of 5 stars
$5.79
-2.2%
$12.54
-116.6%
-67.9%$2.70B$513.09M-3.032,100
USNA
USANA Health Sciences
2.3598 of 5 stars
$97.82
-0.8%
$124.00
-26.8%
+12.9%$1.90B$1.13B14.931,943
CRON
Cronos Group
1.6565 of 5 stars
$3.43
-4.1%
$9.00
-162.4%
-67.8%$1.29B$46.72M-8.37665Analyst Downgrade
ACB
Aurora Cannabis
1.6198 of 5 stars
$4.46
-6.5%
$7.26
-62.9%
-58.1%$884.77M$191.43M-1.711,761News Coverage
SNDL
Sundial Growers
1.6864 of 5 stars
$0.48
-8.4%
$0.78
-62.1%
-25.9%$793.59M$45.48M-2.66394Short Interest ↓
Gap Down
CDXC
ChromaDex
1.8448 of 5 stars
$2.76
-6.9%
$13.00
-371.0%
-43.7%$188.48M$59.26M-6.42110News Coverage
Gap Up
HEXO
HEXO
1.5532 of 5 stars
$0.53
-7.6%
$6.63
-1,158.1%
-92.1%$187.49M$97M-0.511,277News Coverage
IMCC
IM Cannabis
1.825 of 5 stars
$2.17
-14.7%
$8.42
-287.9%
N/A$147.96M$11.86M-2.862,020Short Interest ↓
Gap Down
NAII
Natural Alternatives International
1.2165 of 5 stars
$12.85
-2.9%
N/A+1.2%$81.79M$178.52M6.95240News Coverage
MTEX
Mannatech
1.7964 of 5 stars
$37.93
-3.7%
N/A+97.4%$72.89M$151.41M9.95226
MDWD
MediWound
1.7581 of 5 stars
$2.43
-2.1%
$7.50
-208.6%
-54.0%$66.19M$21.76M-6.0775News Coverage
Gap Up
BON
Bon Natural Life
0 of 5 stars
$3.52
-8.2%
N/AN/A$28.16M$18.22M0.008,787High Trading Volume
HAPP
Happiness Biotech Group
1.3265 of 5 stars
$0.42
-21.4%
N/A-78.5%$13.45M$71.49M0.00151Short Interest ↓
News Coverage
Gap Up
High Trading Volume
This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.